We are testing whether GLP-1 receptor agonists can help reverse metabolic syndrome in patients on the kidney transplant waiting list. This study will evaluate changes in health and safety over 3 to 6 months.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metabolic syndrome is a group of conditions that occur together, increasing the risk of heart disease, stroke, and diabetes. In patients waiting for kidney transplantation, it can complicate their health status and affect transplant outcomes.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.